Hemoglobin C trait is a rare blood disorder that affects a small number of people worldwide. It is caused by a mutation in the gene that codes for hemoglobin, the protein in red blood cells that carries oxygen throughout the body. This mutation results in the production of a slightly different form of hemoglobin, called hemoglobin C. People with hemoglobin C trait have no symptoms, but can pass the trait to their children. In this article, we will take a closer look at hemoglobin C trait and explore the potential risks associated with this rare disorder.
Hemoglobin C trait is a genetic condition caused by a mutation in the gene that codes for hemoglobin, the protein in red blood cells that carries oxygen throughout the body. This mutation results in the production of a slightly different form of hemoglobin, called hemoglobin C. People with hemoglobin C trait have no symptoms, but can pass the trait to their children. Hemoglobin C trait is most common in people of African, Mediterranean, and Middle Eastern descent. It is estimated that about 1 in 250 people of African descent have the trait, while about 1 in 500 people of Mediterranean and Middle Eastern descent have the trait.
Hemoglobin C trait is usually diagnosed through a simple blood test. If the test shows that the individual has hemoglobin C trait, they will not need any further treatment. However, it is important for people with hemoglobin C trait to be aware of the potential risks associated with the disorder. People with hemoglobin C trait should be monitored for any signs of anemia, which can be caused by a decrease in the number of red blood cells in the body. Anemia can lead to fatigue, shortness of breath, and paleness. If anemia is suspected, a doctor may recommend a blood transfusion to replace the missing red blood cells.
People with hemoglobin C trait are at an increased risk of developing a rare form of anemia called hemolytic anemia. This condition occurs when red blood cells are destroyed faster than they can be replaced, leading to a decrease in the number of red blood cells in the body. Hemolytic anemia can cause fatigue, shortness of breath, paleness, jaundice, and dark urine. If left untreated, this condition can be life-threatening. People with hemoglobin C trait are also at an increased risk of developing gallstones. Gallstones are hardened deposits of bile, a fluid produced by the liver to help digest fat. They can cause pain in the upper right side of the abdomen, nausea, and vomiting. In addition, people with hemoglobin C trait are at an increased risk of developing thalassemia, a group of inherited blood disorders that can cause anemia, fatigue, and other symptoms. Thalassemia can be life-threatening if left untreated.
Hemoglobin C trait is a rare blood disorder caused by a mutation in the gene that codes for hemoglobin, the protein in red blood cells that carries oxygen throughout the body. People with hemoglobin C trait have no symptoms, but can pass the trait to their children. It is important for people with hemoglobin C trait to be aware of the potential risks associated with the disorder, including an increased risk of hemolytic anemia, gallstones, and thalassemia. If any of these conditions are suspected, a doctor should be consulted for diagnosis and treatment.
1.
EBCC: European Breast Cancer Conference
2.
For patients with prostate cancer, long-term follow-up helps identify treatment side effects.
3.
Data-driven risk stratification guides childhood brain tumor treatment, reducing side effects
4.
Adult survivors of childhood cancer are at high risk for cognitive impairment, according to JAMA.
5.
Report: High risk of lung cancer from respirable crystalline silica even below the current occupational exposure limit
1.
The Essential Guide to Understanding Fibrinogen and Its Role in Blood Clotting
2.
Essential Techniques in Oncology and Quality Improvement
3.
Tumor Ecosystem Activity Biomarkers in Oncology
4.
Beta-2 Microglobulin: Function, Role in Disease & Clinical Significance Explained
5.
Advancements in Cancer Treatment and Survival Outcomes for Acute Myeloid Leukemia
1.
International Conference on Oncology, Cancer Prevention and Public Health
2.
International Conference on Cancer Nursing and Rehabilitation Strategies
3.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
4.
International Conference on Innovations in Critical Care for Oncology and Cardiology
5.
International Symposium on Oncology, Cardiology and Critical Care Innovations
1.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV
2.
How Nutrition Can Support Patients During Cancer Care
3.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V
4.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part III
5.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation